A study assessed different treatment modalities for patients with sinonasal DLBCL (SN-DLBCL). “Treatment protocol selection differs between early‐ and late‐stage SN‐DLBCL patients. Early‐stage patients receiving chemotherapy may benefit from immunotherapy as part of their treatment paradigm,” the study authors wrote in their conclusion.
Read more.
